Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.

Wilms tumor (WT) is a genetically heterogeneous childhood kidney tumor. Several genetic alterations have been identified in WT patients, including inactivating mutations in WT1 and loss of heterozygosity or loss of imprinting at 11p15, which results in biallelic expression of IGF2. However, the mechanisms by which one or a combination of genetic alterations results in tumorigenesis has remained challenging to determine, given the lack of a mouse model of WT. Here, we engineered mice to sustain mosaic, somatic ablation of Wt1 and constitutional Igf2 upregulation, mimicking a subset of human tumors. Mice with this combination of genetic alterations developed tumors at an early age. Mechanistically, Wt1 ablation blocked mesenchyme differentiation, and increased Igf2 expression upregulated ERK1/2 phosphorylation. Importantly, a subset of human tumors similarly displayed upregulation of ERK1/2 phosphorylation, which suggests ERK signaling might contribute to WT development. Thus, we have generated a biologically relevant mouse model of WT and defined one combination of driver alterations for WT. This mouse model will provide a powerful tool to study the biology of WT initiation and progression and to investigate therapeutic strategies for cancers with IGF pathway dysregulation.

[1]  David Housman,et al.  WT-1 is required for early kidney development , 1993, Cell.

[2]  D. Hanahan,et al.  Deregulation of both imprinted and expressed alleles of the insulin–like growth factor 2 gene during β–cell tumorigenesis , 1995, Nature Genetics.

[3]  K. Lyons,et al.  A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. , 1995, Genes & development.

[4]  C. Laclef,et al.  Six1 is required for the early organogenesis of mammalian kidney , 2003, Development.

[5]  C. Englert,et al.  The Wilms tumor suppressor gene wt1 is required for development of the spleen , 1999, Current Biology.

[6]  Charles A Powell,et al.  Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. , 2002, The American journal of pathology.

[7]  C. Amos,et al.  Frequent Association of β-Catenin and WT1 Mutations in Wilms Tumors , 2000 .

[8]  A. Feinberg,et al.  An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor , 2007, Science.

[9]  E. Batourina,et al.  Foxd1-dependent signals control cellularity in the renal capsule, a structure required for normal renal development , 2005, Development.

[10]  R. Kooijman.  Regulation of apoptosis by insulin-like growth factor (IGF)-I. , 2006, Cytokine & growth factor reviews.

[11]  M. Cleary,et al.  Pbx1 regulates nephrogenesis and ureteric branching in the developing kidney. , 2003, Developmental biology.

[12]  A. Feinberg,et al.  The genetics of BWS associated tumors , 1999 .

[13]  D. Housman,et al.  Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor , 2005, Nature Genetics.

[14]  D. Hanahan,et al.  A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.

[15]  A. McMahon,et al.  Atlas of gene expression in the developing kidney at microanatomic resolution. , 2008, Developmental cell.

[16]  Joe C. Adams,et al.  Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia , 1999, Nature Genetics.

[17]  N. Hastie,et al.  Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. , 2003, Human molecular genetics.

[18]  P. Gruss,et al.  Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system. , 1990, Development.

[19]  G. Dressler,et al.  Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney , 2006, The EMBO journal.

[20]  V. Macaulay,et al.  Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer , 2008 .

[21]  H. Aburatani,et al.  Identification of kidney mesenchymal genes by a combination of microarray analysis and Sall1-GFP knockin mice , 2004, Mechanisms of Development.

[22]  V. Huff.  Wilms tumor genetics. , 1998, American journal of medical genetics.

[23]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[24]  Maria Vernucci,et al.  Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome , 2004, Nature Genetics.

[25]  A. McMahon,et al.  Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. , 2008, Cell stem cell.

[26]  G. Dressler,et al.  Differential expression and function of cadherin-6 during renal epithelium development. , 1998, Development.

[27]  A. Feinberg,et al.  Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk , 2007, Proceedings of the National Academy of Sciences.

[28]  A. McMahon,et al.  Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. , 2005, Developmental cell.

[29]  A. McMahon,et al.  Distinct and sequential tissue-specific activities of the LIM-class homeobox gene Lim1 for tubular morphogenesis during kidney development , 2005, Development.

[30]  M. von Knebel Doeberitz,et al.  Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. , 1999, Cancer research.

[31]  E. Lai,et al.  Essential role of stromal mesenchyme in kidney morphogenesis revealed by targeted disruption of Winged Helix transcription factor BF-2. , 1996, Genes & development.

[32]  M. Little,et al.  Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1 , 2002, Oncogene.

[33]  A. Knudson,et al.  Mutation and cancer: a model for Wilms' tumor of the kidney. , 1972, Journal of the National Cancer Institute.

[34]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[35]  S. Sen,et al.  Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle , 2006, Nucleic acids research.

[36]  Amy Bernard,et al.  Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour , 1993, Nature Genetics.

[37]  Andrew P McMahon,et al.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. , 2002, Developmental biology.

[38]  Y. Arai,et al.  Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities , 2008, Genes, chromosomes & cancer.

[39]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[40]  Fei Gao,et al.  The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis , 2006, Proceedings of the National Academy of Sciences.

[41]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Eccles,et al.  Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour , 1993, Nature.

[43]  P. D'Amore,et al.  IGF2: epigenetic regulation and role in development and disease. , 2008, Cytokine & growth factor reviews.

[44]  J. Davies,et al.  Erk MAP kinase regulates branching morphogenesis in the developing mouse kidney. , 2001, Development.

[45]  S. Tilghman,et al.  Disruption of imprinting caused by deletion of the H19 gene region in mice , 1995, Nature.

[46]  W. W. Nichols,et al.  Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor. , 1987, American journal of human genetics.

[47]  W. Gerald,et al.  The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin , 1999, Cell.

[48]  J. Schalken,et al.  Alterations in Expression of Cadherin–6 and E–Cadherin during Kidney Development and in Renal Cell Carcinoma , 2000, European Urology.

[49]  L. Strong,et al.  Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. , 1987, American journal of human genetics.

[50]  N. Nowak,et al.  Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations , 1994, Nature Genetics.

[51]  A. Feinberg,et al.  Erratum: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour , 1994, Nature Genetics.

[52]  P. Gruss,et al.  Pax-2 controls multiple steps of urogenital development. , 1995, Development.

[53]  V. Huff,et al.  Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one‐third of tumors , 2008, Genes, chromosomes & cancer.

[54]  A. McMahon,et al.  Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4 , 1994, Nature.